Key Takeaways MIRM posted a Q2 loss of $0.12 per share, which beat estimates and narrowed from$0.52 a year ago.Q2 revenues rose 64.1% Y/Y to $127.8M, fueled by strong Livmarli and bile acid product sales.MIRM lifted 2025 revenue guidance to$490M-$510M, up from the previous$435M-$450M range.Mirum Pharmaceuticals (MIRM) reported a loss of 12 cents per share for the second quarter of 2025, much narrower than the Zacks Consensus Estimate of a loss of 31 cents. The company had incurred a loss of 52 cents per ...